{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:34:15Z","timestamp":1792096455402,"version":"4.4.0"},"reference-count":130,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":168,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Secondary thrombotic microangiopathies (TMAs) represent a heterogeneous group of diseases associated with a high risk of kidney failure and death despite available therapeutic strategies. Strong evidence implicates complement activation in the pathogenesis of secondary TMA, and emerging data increasingly suggest that pharmacological blockade of the complement improves the outcomes in patients with secondary TMA. Certain forms of secondary TMA, including postpartum TMA, TMA with coexisting hypertensive emergency and de novo TMA after kidney transplantation exhibit a high prevalence of pathogenic variants in complement genes, similar to those observed in primary atypical haemolytic uraemic syndrome. These conditions should be considered as complement-mediated TMA triggered by pregnancy or transplantation or in which severe hypertension represents a symptom rather than the aetiology of TMA. Their optimal management relies on early initiation of complement inhibition. Other aetiologies of secondary TMA (i.e. autoimmune diseases, haematopoietic stem cell transplantation, drugs, infections) are typically not linked with complement gene variants and their management primarily focuses on removal of the culprit trigger or treatment of the underlying condition. While well-designed trials are still awaited, a growing body of evidence suggests that complement activation is also involved in the pathophysiology of these diseases. Complement inhibitors, which have been associated with better outcomes, should be considered in patients with severe (life- or organ-threatening TMA) or refractory secondary TMA despite adequate management of the underlying condition. This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as a therapeutic strategy.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf091","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:14:05Z","timestamp":1747124045000},"page":"2193-2206","source":"Crossref","is-referenced-by-count":22,"title":["Complement activation in secondary thrombotic microangiopathies"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-1989","authenticated-orcid":false,"given":"Johann","family":"Morelle","sequence":"first","affiliation":[{"name":"Division of Nephrology, University Hospitals Namur (CHU UCL Namur) , Namur ,","place":["Belgium"]},{"name":"de Duve Institute , UCLouvain, Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-9663","authenticated-orcid":false,"given":"Fernando","family":"Caravaca-Fontan","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) Department of Nephrology, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Fakhouri","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, CHUV, University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[{"name":"Limassol General Hospital Department of Nephrology, , State Health Services Organization, Limassol ,","place":["Cyprus"]},{"name":"University of Nicosia Medical School Department of Basic and Clinical Sciences, , Nicosia ,","place":["Cyprus"]},{"name":"Aretaieio Hospital, National and Kapodistrian University of Athens Medical School , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[{"name":"Medicine and Caring Sciences, Link\u00f6ping University Department of Health, , Link\u00f6ping ,","place":["Sweden"]},{"name":"Karolinska University Hospital and CLINTEC Karolinska Institutet Department of Renal Medicine, , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Rheinisch-Westf\u00e4lische Technische Hochschule (RWTH) Aachen University Hospital , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0362-8154","authenticated-orcid":false,"given":"Safak","family":"Mirioglu","sequence":"additional","affiliation":[{"name":"Aziz Sancar Institute of Experimental Medicine, Istanbul University Department of Immunology, , Istanbul ,","place":["Turkey"]},{"name":"Division of Nephrology, Bezmialem Vakif University Hospital , Istanbul ,","place":["Turkey"]},{"name":"Istanbul Faculty of Medicine, Istanbul University Division of Nephrology, Department of Internal Medicine, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9377-4133","authenticated-orcid":false,"given":"Sarah M","family":"Moran","sequence":"additional","affiliation":[{"name":"Cork University Hospital, University College Cork , Cork ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-494X","authenticated-orcid":false,"given":"Stefanie","family":"Steiger","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-University Hospital Munich Division of Nephrology, Department of Medicine IV, , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-1692","authenticated-orcid":false,"given":"Kate I","family":"Stevens","sequence":"additional","affiliation":[{"name":"Queen Elizabeth University Hospital Glasgow Renal and Transplant Unit, , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2195","authenticated-orcid":false,"given":"Onno Y K","family":"Teng","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Nephrology, , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selda","family":"Aydin","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint-Luc Department of Pathology, , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Java","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Washington University School of Medicine Department of Medicine, , St. Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-2753","authenticated-orcid":false,"given":"Sjoerd A M E G","family":"Timmermans","sequence":"additional","affiliation":[{"name":"Expert Center for Immune-mediated Kidney Diseases and Vasculitis, Maastricht University Medical Center , Maastricht ,","place":["The Netherlands"]},{"name":"Cardiovascular Research Institute Maastricht Department of Biochemistry, , Maastricht , and","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[{"name":"Link\u00f6ping University Department of Health, Medicine and Caring Sciences, , Link\u00f6ping ,","place":["Sweden"]},{"name":"Nephrology and Hypertension, Medical University of Innsbruck Department of Internal Medicine IV, , Innsbruck ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"2025102920024019500_bib1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib3","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.kint.2024.02.014","article-title":"Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies","volume":"105","author":"Maisons","year":"2024","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib4","doi-asserted-by":"publisher","first-page":"100690","DOI":"10.1016\/j.modpat.2024.100690","article-title":"Etiology and outcomes of kidney-limited and systemic thrombotic microangiopathy","volume":"38","author":"van Doorn","year":"2025","journal-title":"Mod Pathol"},{"key":"2025102920024019500_bib5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2215\/CJN.0000000000000182","article-title":"Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies","volume":"18","author":"Werion","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102920024019500_bib6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","article-title":"An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group","volume":"106","author":"Nester","year":"2024","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2025102920024019500_bib9","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"2025102920024019500_bib10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"2025102920024019500_bib11","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2025102920024019500_bib12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","article-title":"Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum","volume":"106","author":"Kavanagh","year":"2024","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and outcomes of thrombotic microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102920024019500_bib15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ckj\/sfz066","article-title":"Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy","volume":"13","author":"Sch\u00f6nermarck","year":"2020","journal-title":"Clin Kidney J"},{"key":"2025102920024019500_bib16","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib17","doi-asserted-by":"publisher","first-page":"566678","DOI":"10.3389\/fmed.2021.566678","article-title":"Retrospective and systematic analysis of causes and outcomes of thrombotic microangiopathies in routine clinical practice: an 11-year study","volume":"8","author":"Henry","year":"2021","journal-title":"Front Med"},{"key":"2025102920024019500_bib18","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"key":"2025102920024019500_bib19","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.ekir.2024.05.016","article-title":"Thrombotic microangiopathy in pregnancy: current understanding and management strategies","volume":"9","author":"Urra","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025102920024019500_bib20","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.kint.2023.12.021","article-title":"A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome\/complement-mediated thrombotic microangiopathy","volume":"105","author":"Che","year":"2024","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib21","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102920024019500_bib22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","article-title":"A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome","volume":"93","author":"Huerta","year":"2018","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib23","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"key":"2025102920024019500_bib24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12882-020-02190-0","article-title":"Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis","volume":"22","author":"G\u00e4ckler","year":"2021","journal-title":"BMC Nephrol"},{"key":"2025102920024019500_bib25","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2025102920024019500_bib26","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib27","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2025102920024019500_bib28","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3324\/haematol.2019.216903","article-title":"Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome","volume":"104","author":"El Karoui","year":"2019","journal-title":"Haematologica"},{"key":"2025102920024019500_bib29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","article-title":"Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy","volume":"75","author":"Timmermans","year":"2020","journal-title":"Hypertension"},{"key":"2025102920024019500_bib30","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","article-title":"Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome","volume":"96","author":"Cavero","year":"2019","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib31","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.kint.2019.07.023","article-title":"Atypical hemolytic uremic syndrome and hypertensive crisis","volume":"96","author":"El Karoui","year":"2019","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib32","doi-asserted-by":"publisher","first-page":"642864","DOI":"10.3389\/fmed.2021.642864","article-title":"Thrombotic microangiopathy after kidney transplantation: an underdiagnosed and potentially reversible entity","volume":"8","author":"\u00c1vila","year":"2021","journal-title":"Front Med"},{"key":"2025102920024019500_bib33","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"2025102920024019500_bib34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ekir.2024.01.013","article-title":"\u201cEculizumab first\u201d in the management of posttransplant thrombotic microangiopathy","volume":"9","author":"Maritati","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025102920024019500_bib35","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.transproceed.2012.09.038","article-title":"Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports","volume":"44","author":"Gonz\u00e1lez-Roncero","year":"2012","journal-title":"Transplant Proc"},{"key":"2025102920024019500_bib36","doi-asserted-by":"publisher","first-page":"3197042","DOI":"10.1155\/2017\/3197042","article-title":"Eculizumab for thrombotic microangiopathy associated with antibody-mediated rejection after ABO-incompatible kidney transplantation","volume":"2017","author":"Lanfranco","year":"2017","journal-title":"Case Rep Transplant"},{"key":"2025102920024019500_bib37","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1111\/ajt.15397","article-title":"Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies","volume":"19","author":"Glotz","year":"2019","journal-title":"Am J Transplant"},{"key":"2025102920024019500_bib38","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial","volume":"19","author":"Marks","year":"2019","journal-title":"Am J Transplant"},{"key":"2025102920024019500_bib39","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ekir.2024.12.031","article-title":"Early thrombotic microangiopathy after ABO-incompatible living donor kidney transplantation","volume":"10","author":"Bertrand","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2025102920024019500_bib40","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMra1404711","article-title":"Renal complications of hematopoietic-cell transplantation","volume":"374","author":"Hingorani","year":"2016","journal-title":"N Engl J Med"},{"key":"2025102920024019500_bib41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"2025102920024019500_bib42","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2025102920024019500_bib43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/TP.0b013e31829807aa","article-title":"Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"96","author":"Laskin","year":"2013","journal-title":"Transplantation"},{"key":"2025102920024019500_bib44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025102920024019500_bib45","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00277-017-3092-9","article-title":"Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"96","author":"Qi","year":"2017","journal-title":"Ann Hematol"},{"key":"2025102920024019500_bib46","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"2025102920024019500_bib47","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"2025102920024019500_bib48","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.bbmt.2017.05.013","article-title":"Acquired complement regulatory gene mutations and hematopoietic stem cell transplant-related thrombotic microangiopathy","volume":"23","author":"Ardissino","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025102920024019500_bib49","doi-asserted-by":"publisher","first-page":"564647","DOI":"10.3389\/fimmu.2020.564647","article-title":"Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"2025102920024019500_bib50","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2141.2007.06588.x","article-title":"Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab","volume":"137","author":"Au","year":"2007","journal-title":"Br J Haematol"},{"key":"2025102920024019500_bib51","first-page":"72","article-title":"Successful treatment of transplant-associated microangiopathy with rituximab","volume":"122","author":"Marr","year":"2009","journal-title":"N Z Med J"},{"key":"2025102920024019500_bib52","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/bmt.2008.25","article-title":"Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura","volume":"41","author":"Carella","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"2025102920024019500_bib53","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/sj.bmt.1703414","article-title":"Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation","volume":"29","author":"Corti","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"2025102920024019500_bib54","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"key":"2025102920024019500_bib55","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1076029615599439","article-title":"Eculizumab in transplant-associated thrombotic microangiopathy","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025102920024019500_bib56","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.13127","article-title":"Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients","volume":"101","author":"Rudoni","year":"2018","journal-title":"Eur J Haematol"},{"key":"2025102920024019500_bib57","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"2025102920024019500_bib58","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA","volume":"143","author":"Jodele","year":"2024","journal-title":"Blood"},{"key":"2025102920024019500_bib59","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025102920024019500_bib60","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0272-6386(12)80885-7","article-title":"Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis","volume":"18","author":"Banfi","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"2025102920024019500_bib61","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2025102920024019500_bib62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025102920024019500_bib63","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3899\/jrheum.220752","article-title":"The role of complement in autoimmune disease-associated thrombotic microangiopathy and the potential for therapeutics","volume":"50","author":"Java","year":"2023","journal-title":"J Rheumatol"},{"key":"2025102920024019500_bib64","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11926-021-00984-1","article-title":"A review of complement activation in SLE","volume":"23","author":"Weinstein","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"2025102920024019500_bib65","doi-asserted-by":"publisher","first-page":"R185","DOI":"10.1186\/ar4016","article-title":"Factor H autoantibodies and deletion of complement factor H-related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome","volume":"14","author":"Foltyn Zadura","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2025102920024019500_bib66","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv"},{"key":"2025102920024019500_bib67","doi-asserted-by":"publisher","first-page":"621609","DOI":"10.3389\/fmed.2020.621609","article-title":"Complement factor I mutation may contribute to development of thrombotic microangiopathy in lupus nephritis","volume":"7","author":"Tseng","year":"2021","journal-title":"Front Med"},{"key":"2025102920024019500_bib68","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1177\/09612033221106301","article-title":"Kidney thrombotic microangiopathy in lupus nephritis: impact on treatment and prognosis","volume":"31","author":"Massicotte-Azarniouch","year":"2022","journal-title":"Lupus"},{"key":"2025102920024019500_bib69","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2025102920024019500_bib70","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12882-020-01888-5","article-title":"A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy","volume":"21","author":"Wright","year":"2020","journal-title":"BMC Nephrol"},{"key":"2025102920024019500_bib71","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.mayocp.2024.10.001","article-title":"Eculizumab improves renal survival in complement-mediated TMA secondary to SLE","volume":"100","author":"Fu","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"2025102920024019500_bib72","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1182\/blood-2024-210086","article-title":"KP104, a bifunctional C5 mAb-factor H fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor-na\u00efve PNH patients: updated results from a phase 2 study at 36\/38 weeks of OBD treatment","volume":"144","author":"Zhang","year":"2024","journal-title":"Blood"},{"key":"2025102920024019500_bib73","doi-asserted-by":"publisher","first-page":"e3595","DOI":"10.1097\/MD.0000000000003595","article-title":"Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy: a case series study","volume":"95","author":"Li","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025102920024019500_bib74","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3899\/jrheum.131210","article-title":"Scleroderma renal crisis","volume":"41","author":"Mouthon","year":"2014","journal-title":"J Rheumatol"},{"issue":"Suppl 3","key":"2025102920024019500_bib75","doi-asserted-by":"publisher","first-page":"iii32","DOI":"10.1093\/rheumatology\/ken483","article-title":"Renal complications and scleroderma renal crisis","volume":"48","author":"Denton","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2025102920024019500_bib76","first-page":"2218","article-title":"Hypocomplementemia in systemic sclerosis\u2014clinical and serological correlations","volume":"34","author":"Hudson","year":"2007","journal-title":"J Rheumatol"},{"key":"2025102920024019500_bib77","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4081\/reumatismo.2008.268","article-title":"Hypocomplementemia in systemic sclerosis","volume":"60","author":"Cuomo","year":"2008","journal-title":"Reumatismo"},{"key":"2025102920024019500_bib78","doi-asserted-by":"publisher","first-page":"e0114856","DOI":"10.1371\/journal.pone.0114856","article-title":"The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study","volume":"10","author":"Scambi","year":"2015","journal-title":"PLoS One"},{"key":"2025102920024019500_bib79","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.humpath.2008.08.001","article-title":"Renal biopsy findings predicting outcome in scleroderma renal crisis","volume":"40","author":"Batal","year":"2009","journal-title":"Hum Pathol"},{"key":"2025102920024019500_bib80","doi-asserted-by":"publisher","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025102920024019500_bib81","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2025102920024019500_bib82","doi-asserted-by":"publisher","first-page":"100753","DOI":"10.1016\/j.xkme.2023.100753","article-title":"Eculizumab use in scleroderma renal crisis with thrombotic microangiopathy: a case report","volume":"6","author":"Trivin-Avillach","year":"2024","journal-title":"Kidney Med"},{"key":"2025102920024019500_bib83","doi-asserted-by":"publisher","first-page":"152256","DOI":"10.1016\/j.semarthrit.2023.152256","article-title":"Studying the role of C5-inhibition therapy in scleroderma renal crisis-induced thrombotic microangiopathy \u2013 a review of literature","volume":"63","author":"Farrukh","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2025102920024019500_bib84","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1007\/s00296-024-05689-z","article-title":"Targeting complement dysregulation: eculizumab in scleroderma renal crisis management-a case-based review","volume":"44","author":"Toker Dincer","year":"2024","journal-title":"Rheumatol Int"},{"key":"2025102920024019500_bib85","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"2025102920024019500_bib86","doi-asserted-by":"publisher","first-page":"18005","DOI":"10.1038\/nrdp.2018.5","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025102920024019500_bib87","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025102920024019500_bib88","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2016.06.026","article-title":"Antiphospholipid syndrome and kidney disease","volume":"91","author":"Bienaim\u00e9","year":"2017","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib89","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1053\/j.ajkd.2019.08.032","article-title":"mTORC pathway activation and effect of Sirolimus on native kidney antiphospholipid syndrome nephropathy: a case report","volume":"76","author":"Dufour","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025102920024019500_bib90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antib13010021","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"13","author":"Jacobs","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"2025102920024019500_bib91","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"key":"2025102920024019500_bib92","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1172\/JCI18817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"key":"2025102920024019500_bib93","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025102920024019500_bib94","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2005-03-1319","article-title":"Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor","volume":"106","author":"Fischetti","year":"2005","journal-title":"Blood"},{"key":"2025102920024019500_bib95","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2009-01-199117","article-title":"Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies","volume":"114","author":"Seshan","year":"2009","journal-title":"Blood"},{"key":"2025102920024019500_bib96","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1177\/0961203312458839","article-title":"C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies","volume":"21","author":"Carrera-Mar\u00edn","year":"2012","journal-title":"Lupus"},{"key":"2025102920024019500_bib97","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/blood-2013-11-537704","article-title":"A non-complement-fixing antibody to \u03b22 glycoprotein I as a novel therapy for antiphospholipid syndrome","volume":"123","author":"Agostinis","year":"2014","journal-title":"Blood"},{"key":"2025102920024019500_bib98","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025102920024019500_bib99","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"2025102920024019500_bib100","doi-asserted-by":"publisher","first-page":"167.e1","DOI":"10.1016\/j.ajog.2006.10.879","article-title":"Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies","volume":"196","author":"Shamonki","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"2025102920024019500_bib101","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/path.2893","article-title":"Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss","volume":"225","author":"Cohen","year":"2011","journal-title":"J Pathol"},{"key":"2025102920024019500_bib102","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"key":"2025102920024019500_bib103","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.autrev.2015.01.008","article-title":"Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature","volume":"14","author":"Viall","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2025102920024019500_bib104","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1093\/rheumatology\/keae178","article-title":"Can complement activation be the missing link in antiphospholipid syndrome?","volume":"63","author":"Venturelli","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025102920024019500_bib105","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"2025102920024019500_bib106","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025102920024019500_bib107","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med"},{"key":"2025102920024019500_bib108","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","article-title":"Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation","volume":"11","author":"Hadaya","year":"2011","journal-title":"Am J Transplant"},{"key":"2025102920024019500_bib109","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025102920024019500_bib110","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.55563\/clinexprheumatol\/ric86c","article-title":"Relevance of inflammatory and complement activation biomarkers profiling in antiphospholipid syndrome patients outside acute thrombosis","volume":"41","author":"Yelnik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025102920024019500_bib111","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/bjh.17783","article-title":"Early use of eculizumab for catastrophic antiphospholipid syndrome","volume":"196","author":"Faguer","year":"2022","journal-title":"Br J Haematol"},{"key":"2025102920024019500_bib112","doi-asserted-by":"publisher","first-page":"103055","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201cCAPS Registry\u201d","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025102920024019500_bib113","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol"},{"key":"2025102920024019500_bib114","doi-asserted-by":"publisher","first-page":"1088031","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025102920024019500_bib115","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"2025102920024019500_bib116","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2025102920024019500_bib117","doi-asserted-by":"publisher","first-page":"E369","DOI":"10.1002\/ajh.27101","article-title":"Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: analysis from a large pharmacovigilance database","volume":"98","author":"Klomjit","year":"2023","journal-title":"Am J Hematol"},{"key":"2025102920024019500_bib118","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025102920024019500_bib119","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2025102920024019500_bib120","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.thromres.2023.02.012","article-title":"Eculizumab in the management of drug-induced thrombotic microangiopathy: a scoping review of the literature","volume":"224","author":"Zafar","year":"2023","journal-title":"Thromb Res"},{"key":"2025102920024019500_bib121","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib122","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/j.ajkd.2021.12.014","article-title":"Complement activation and thrombotic microangiopathy associated with monoclonal gammopathy: a national French case series","volume":"80","author":"Martins","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025102920024019500_bib123","doi-asserted-by":"publisher","first-page":"sfad306","DOI":"10.1093\/ckj\/sfad306","article-title":"The spectrum of thrombotic microangiopathy related to monoclonal gammopathy","volume":"17","author":"van Doorn","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025102920024019500_bib124","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"2025102920024019500_bib125","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.kint.2018.08.001","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"key":"2025102920024019500_bib126","doi-asserted-by":"publisher","first-page":"e140711","DOI":"10.1172\/jci.insight.140711","article-title":"The complement system in COVID-19: friend and foe?","volume":"5","author":"Java","year":"2020","journal-title":"JCI Insight"},{"key":"2025102920024019500_bib127","doi-asserted-by":"publisher","first-page":"eadg7942","DOI":"10.1126\/science.adg7942","article-title":"Persistent complement dysregulation with signs of thromboinflammation in active long Covid","volume":"383","author":"Cervia-Hasler","year":"2024","journal-title":"Science"},{"key":"2025102920024019500_bib128","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1016\/j.ekir.2024.07.034","article-title":"Systematic review of individual patient data COVID-19 infection and vaccination-associated thrombotic microangiopathy","volume":"9","author":"Moradiya","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025102920024019500_bib129","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102920024019500_bib130","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf091\/63196405\/gfaf091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/11\/2193\/65001689\/gfaf091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/11\/2193\/65001689\/gfaf091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:02:51Z","timestamp":1761782571000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/11\/2193\/8132922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":130,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf091","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,5,15]]}}}